205 related articles for article (PubMed ID: 10221367)
1. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
2. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
3. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
4. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
7. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
8. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
9. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
[No Abstract] [Full Text] [Related]
10. Effect of protease inhibitors on the sense of taste.
Schiffman SS; Zervakis J; Heffron S; Heald AE
Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
[TBL] [Abstract][Full Text] [Related]
11. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Bonfanti P; Valsecchi L; Parazzini F; Carradori S; Pusterla L; Fortuna P; Timillero L; Alessi F; Ghiselli G; Gabbuti A; Di Cintio E; Martinelli C; Faggion I; Landonio S; Quirino T
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):236-45. PubMed ID: 10839659
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Lai S; Lai H; Celentano DD; Vlahov D; Ren S; Margolick J; Lima JA; Bartlett JG
AIDS Patient Care STDS; 2003 May; 17(5):211-9. PubMed ID: 12816615
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 protease inhibitors.
Deeks SG; Volberding PA
AIDS Clin Rev; 1997-1998; ():145-85. PubMed ID: 9305448
[No Abstract] [Full Text] [Related]
14. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
15. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and clinical experience with saquinavir.
Kravcik S
Expert Opin Pharmacother; 2001 Feb; 2(2):303-15. PubMed ID: 11336588
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions of HIV protease inhibitors.
Malaty LI; Kuper JJ
Drug Saf; 1999 Feb; 20(2):147-69. PubMed ID: 10082072
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection.
Misson J; Clark W; Kendall MJ
J Clin Pharm Ther; 1997 Apr; 22(2):109-17. PubMed ID: 9373809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
